2024 ASGCT Presentation

Streamlining the CRISPR Editing Process in an eTIL Cell Therapy

American Society for Gene and Cell Therapy annual meeting
Baltimore, Maryland, USA
May 9, 2024

Ben Askin presents KSQ Therapeutics' work developing a scalable cGMP process for their engineered tumor-infiltrating lymphocyte (eTIL™) cell therapy.

Watch the ASGCT presentation

ASGCT presentation slide overlay


Photograph of Ben Askin

Ben Askin

Scientist, Cellular Process Development, at KSQ Therapeutics

Ben Askin is a seasoned scientist with over nine years of experience in pharmaceuticals and biotechnology. Currently serving as a key member of the Cellular Process Development Team at KSQ Therapeutics, Ben brings a wealth of expertise spanning the scientific, manufacturing and quality domains.

During his tenure at Kite Gilead EU in Hoofddorp, Netherlands, Ben played a pivotal role in the successful launch of the European manufacturing site for the groundbreaking CAR-T therapy, Yescarta®. His contributions were instrumental in facilitating a seamless technical transfer and ensuring compliance during the European Medicines Agency's site inspections.

Ben holds a Bachelor of Science degree in Chemistry and Psychology from The College of New Jersey.


Have more questions?

Send your question to one of our cell engineering experts.